Antisense oligonucleotide targeting interleukin 4 receptor and use thereof

By designing antisense oligonucleotide molecules that target the interleukin-4 receptor, the expression of IL-4Rα is specifically inhibited, which solves the problem of poor treatment effect in severe asthma and provides a highly effective and long-lasting treatment option.

WO2026138437A1 Publication Date: 2026-07-02LNCTAC CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/140152
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-25
Filing Date
2025-12-04
Publication Date
2026-07-02

AI Technical Summary

Technical Problem

Current treatments for severe asthma are not ideal, especially for T2 asthma. Furthermore, existing targeted therapies require long-term administration, which does not meet clinical needs, and there is a lack of effective treatment options for small airways.

Method used

By designing antisense oligonucleotide (ASO) molecules that target the interleukin-4 receptor (IL-4Rα), and inhibiting its expression by specifically pairing with specific regions of IL-4Rα mRNA and Pre-mRNA, drugs suitable for non-T2 type severe asthma can be developed.

Benefits of technology

Significantly inhibiting IL-4Rα expression provides an effective treatment for severe asthma, reducing treatment costs and the frequency of drug use, thus meeting clinical needs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.
Need to check novelty before this filing date? Find Prior Art